Long‐term follow‐up of patients with subacute sclerosing panencephalitis treated with inosiplex

Publisher Website
Google Scholar
Abstract
During the past five years, 15 patients with subacute sclerosing panencephalitis (SSPE) were treated with inosiplex. Using a disability index specifically designed for the disease, this study monitored the course of SSPE in each patient before and during inosiplex therapy. Posttreatment follow‐up ranged from 2 to 144 months. Inosiplex had an apparently beneficial effect on morbidity and mortality in 10 of the 15 patients tested. Eight improved immediately after treatment, 2 had a delayed improvement, and 1 patient stabilized. Four patients followed a typical course for SSPE and died a mean of 9 months after onset. Treatment was not associated with adverse reactions. Due to its low risk‐benefit ratio, inosiplex is recommended for continuous use in SSPE even after extended remissions.